Oxymetazoline - Allergan

Drug Profile

Oxymetazoline - Allergan

Alternative Names: AGN-199201; Oxymetazoline hydrochloride; Rhofade; V-101

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vicept Therapeutics
  • Developer Allergan
  • Class Decongestants; Imidazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Erythema
  • Phase II Presbyopia

Most Recent Events

  • 31 Oct 2017 Allergan completes a phase II trial for Presbyopia (Combination therapy) in USA (Opthalmic) (NCT02780115)
  • 18 Oct 2017 Allergan completes a phase II trial in Presbyopia (Combination therapy) in USA (Ophthalmic) (NCT02595528)
  • 23 May 2017 Launched for Erythema (associated with rosacea) in USA (Topical,cream)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top